CTIS2023-503846-30-00招募中1 期
A Phase 1b/2 Open-Label Study of Samuraciclib in Combination with Elacestrant in Participants with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer - CT7001_003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of carcinoma of the breast with evidence of metastatic or locally advanced disease, not amenable to resection or radiation therapy with curative intent., Documentation of ER-positive with or without progesterone receptor (PgR)-positive tumor based on most recent tumor biopsy utilizing an assay consistent with local standards. • ER-positivity is defined as =10% positive stained cells regardless of the PgR-result (Hammond et al., 2010; Allison et al., 2020)., Documentation of HER2 negativity based on local testing on most recent tumor biopsy. • HER2-negativity is defined as immunohistochemistry score 0/1+ or negative by in situ hybridization (fluorescent in situ hybridization [FISH]/chromogenic in situ hybridization [CISH]/silver-enhanced in situ hybridization [SISH] defined as a HER2/chromosome 17 FISH (CEP17) ratio <2 or for single probe assessment a HER2 copy number <4 • Biopsy of first recurrence is recommended, in case no tumor biopsy was performed after initial resection of the primary tumor, the original tumor tissue serves as basis for assessment of ER/PgR and HER2 status • Assessment of ER, PgR, and HER2 status will be based on results from local pathology laboratories., Must have 1 of the following as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1: • Measurable disease • Bone only disease with evaluable lesions. Participants who have had prior radiation to bone must have at least 1 evaluable lesion in a nonirradiated area. For clarity bone lesions must be evaluable, but do not need to be measurable., Participants must have documented objective disease progression while on or within 6 months after the end of the most recent therapy., Participants must have received an aromatase inhibitor in combination with a CDK4/6 inhibitor in one of the following settings: • Participants must have received at least 6 months of clinical benefit on this line of therapy to be eligible. Participants who received <6 months CDK4/6 inhibitor due to tolerability issues may still enter the study provided at least 6 months aromatase inhibitor was received. • Adjuvant setting, if the disease-free interval between initiation of endocrine therapy and first line treatment of locally advanced or metastatic disease was >24 months., Expected life expectancy of greater than 12 weeks.
排除标准
- •Prior therapy with a Selective estrogen receptor degrader (SERD) or other investigational SERDs or alike agents in the advanced/metastatic setting., Prior treatment with cytotoxic chemotherapy for locally advanced or metastatic BC., Prior treatment with a mammalian target of rapamycin (mTOR) inhibitor including, but not limited to, everolimus., Inadequate hepatic, renal, bone marrow, or cardiac function, specified as follows: • Hepatic • Renal • Bone marrow • Cardiovascular, Known central nervous system metastases, carcinomatous meningitis, or leptomeningeal disease., More than 1 line of endocrine treatment for locally advanced or metastatic disease treatment, Inflammatory BC, Prior treatment with a phosphatidylinositol-3-kinase (PI3K) inhibitor, including, but not limited to alpelisib., Prior treatment with an AKT (protein kinase B, or Akt) inhibitor, including, but not limited to capivasertib.
研究者
相似试验
已完成
1 期
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast CancerLocally Advanced Breast CancerMetastatic Breast CancerBreast CancerNCT05963997Carrick Therapeutics Limited49
进行中（未招募）
1 期
sabatolimab as a treatment for patients with acute myeloid leukemia and presence of measurable residual disease after allogeneic stem cell transplantatioEUCTR2020-000869-17-DEovartis Pharma AG59
进行中（未招募）
1 期
sabatolimab as a treatment for patients with acute myeloid leukemia and presence of measurable residual disease after allogeneic stem cell transplantatioParticipants with AML/secondary AML who are in complete remission with positive measurable residual disease post-allogeneic hematopoietic stem cell transplantation (MRD+ post aHSCT)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2020-000869-17-ITOVARTIS PHARMA AG59
进行中（未招募）
1 期
A Phase I/II Study of Sirolimus (Rapamune TM) in Combination with Cyclophosphamide and Dexamethasone in Relapsed Myeloma - SCD1 TrialPlasma Cell MyelomaEUCTR2005-000656-33-GBRoyal Devon and Exeter NHS Foundation Trust18
进行中（未招募）
不适用
A Phase II, Single Arm, Open label Study of Cyclophosphamide, Vincristine, Liposomal Doxorubicine (Myocet™) and Prednisone plus Rituximab in Fortnightly Regimen (R-COMP-14), as First Line of therapy for Patients with Aggressive Non Hodgkin’s Lymphoma (NHL).Dose-dense modified R-CHOP regimen (R-COMP) in patients with aggressive NHL.EUCTR2004-001199-37-ES(GOTEL) Grupo Oncológico para el tratamiento y estudio de los linfomas75